Funding for this research was provided by:
Svenska Forskningsrådet Formas
Hjärnfonden
Stockholm Brain Institute
Autism and Asperger Association Stockholm
Queen Silvia Jubilee Fund
Solstickan Foundation
PRIMA Child and Adult Psychiatry
the Pediatric Research Foundation at Astrid Lindgren Children’s Hospital
Sällskapet Barnavård
the Swedish Foundation for Strategic Research
Jerring Foundation
the Swedish Order of Freemasons
Kempe- Carlgrenska Foundation
Sunnderdahls Handikappsfond
The Jeansson Foundation
EU-AIMS
the Innovative Medicines Initiative Joint Undertaking (115300)
the European Union’s Seventh Framework Programme (FP7/2007–2013)
the European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions
Autism Speaks
Article History
Received: 30 May 2019
Accepted: 26 November 2019
First Online: 6 December 2019
Compliance with Ethical Standards
:
: Sven Bölte discloses that he has in the last 5 years acted as an author, consultant or lecturer for Shire, Medice, Roche, Eli Lilly, Prima Psychiatry, GLGroup, System Analytic, Ability Partner, Kompetento, Expo Medica, Clarion Healthcare, Abilia, and Prophase. He receives royalties for text books and diagnostic tools from Huber/Hogrefe, Kohlhammer and UTB. Pei-Yin Pan, Kristiina Tammimies, and Sven Bölte declare that they have no conflict of interest related to this article.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants and/or their legal guardians included in the study.